Primary outcomes at 12 weeks

In this episode, we explore pramipexole—a Parkinson's medication—as a promising add-on treatment for treatment-resistant bipolar depression. Could a dopamine agonist be the unexpected solution when standard mood stabilizers and antipsychotics fail? We examine the PAX-BD trial's findings, safety concerns, and practical clinical applications.

Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 78
• Treatment-Resistant Bipolar Depression: Is Adjunctive Pramipexole An Option?